PharmaCielo Makes Initial Shipments to two Brazilian Customers


Ryan Allway

April 26th, 2021

News


  • Shipments to established Pharmaceutical and Phyto-Therapeutics companies will offer PharmaCielo and its APIs1 early integration into the supply chain.
  • Shipments followed an audit by the Phyto-Therapeutics customer, that confirmed PharmaCielo’s compliance with Brazilian GMP standards.

 

TORONTO, and RIONEGRO, ColombiaApril 26, 2021 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed initial shipments to two customers in Brazil following an audit to confirm PharmaCielo’s compliance with Brazilian Good Manufacturing Practices (“GMP”) standards.  The first shipment recently arrived at one of Brazil’s largest Phyto-Therapeutics companies. This customer intends to integrate PharmaCielo’s APIs into custom formulations for current and future product registry and sale in the local market. The second shipment recently arrived at a large Pharmaceutical company that already has a CBD product in-market and intends to use PharmaCielo as a key supplier.

 

 

“These initial pre-commercial shipments, and the GMP confirmation that was conducted by one of the companies, provide further confirmation of PharmaCielo’s product quality and the excellence of its production processes,” said Henning von Koss, CEO of PharmaCielo Ltd. “Further, these relationships demonstrate that larger and more sophisticated end-product producers are actively coming to market looking for a reliable source of high-quality extracts and formulation expertise.  PharmaCielo is positioned to supply these customers with consistent quality, at industry-leading scale. We look forward to working with both customers over the next several months as their teams integrate our APIs into their custom formulations.”

 

 

About the Brazilian Medical Cannabis Market

According to research firm Prohibition Partners’ LATAM report2, with a population of more than 211 million, Brazil represents the largest potential market in Latin America for the cannabis industry and it is estimated that the Brazilian medical cannabis user base could reach close to 3 million people in the next few years. A recent analysis3 by the research firm, found that the number of both cannabis patient associations and medical cannabis prescriptions in Brazil are on the rise with the latter experiencing a 135% increase from 2019 to over 14,500 prescriptions.

 

_________________________
1 Active Pharmaceutical Ingredients
2 Prohibition Partners – The Latin America And Caribbean Cannabis Report 
3 Prohibition Partners – The Key Challenges Facing the Brazilian Cannabis Market (March 26, 2021)

 

 

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre located in Rionegro, Colombia.

 

The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

 

 

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as “expects”, “is expected”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements as to the intent of one customer of PharmaCielo to incorporate PharmaCielo’s products into that customer’s own formulations and the intent of another customer of PharmaCielo to use PharmaCielo as a key supplier. These statements are based on PharmaCielo’s management’s reasonable assumptions and beliefs in light of the information available at the time such statements are being made. By its very nature, forward-looking information requires the making of assumptions and is subject to inherent risks and uncertainties which give rise to the possibility that PharmaCielo’s predictions, expectations or conclusions will not prove to be accurate, that PharmaCielo’s assumptions may not be correct and that PharmaCielo’s objectives, strategic goals and priorities will not be achieved. Although PharmaCielo believes that the predictions, expectations or conclusions reflected in the forward-looking information are reasonable, it can give no assurance that such matters will prove to have been correct. Such forward-looking information is not fact but only reflects management’s estimates and expectations. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo’s development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, obtaining TSXV approval, the inability to export or distribute products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company’s products, risks associated with global economic instability relating to COVID-19, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo’s market and other risks discussed or referred to under the heading “Risk Factors” in PharmaCielo’s Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PharmaCielo Ltd.

 

Renseignements: Henning von Koss, CEO, +1 416-864-6116, PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1 416-602-4092, [email protected] ; Colombia: Giselle Díaz Bermúdez, SPR Group, + 57 310 859 5468, [email protected] ; Investor Inquiries:[email protected]

Liens connexes

http://www.pharmacielo.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading